Actuate Therapeutics provides advanced research for the treatment of high-impact cancers and neurodegenerative diseases.
Actuate Therapeutics has raised $11.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in October 2026.
Actuate Therapeutics's investors include Kairos Ventures, Bios Partners, DEFTA Partners, Craig-Hallum Capital Group, TCA Venture Group.
Actuate Therapeutics is headquartered in Fort Worth, United States.
Actuate Therapeutics provides advanced research for the treatment of high-impact cancers and neurodegenerative diseases.
Actuate Therapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Actuate Therapeutics — Funding & Investors." VCBacked, October 27, 2026, https://www.vcbacked.co/company/actuate-therapeutics. Accessed November 14, 2026.
VCBacked. (2026). Actuate Therapeutics — Funding & Investors. Retrieved November 14, 2026, from https://www.vcbacked.co/company/actuate-therapeutics
{{cite web |title=Actuate Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/actuate-therapeutics |website=VCBacked |access-date=November 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Actuate Therapeutics? Request a listing update